Abstract
Few therapeutic drugs, other than metronidazole and close derivatives, are currently available to treat trichomoniasis. Trichomonas vaginalis is known to have a primitive ribosome based on small subunit ribosomal DNA sequence comparisons. Targeting ribosomal subunits, the aminoglycosides neomycin and geneticin (G418, distinct from gentamycin) were tested for activity against T. vaginalis. While neomycin had no effect, G418 was effective in killing cultured T. vaginalis cells at doses intermediate between those previously effective against prokaryotes and eukaryotes. G418 cytotoxicity requires further study before recommending this agent as topically applied therapy in refractory patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
